[Difficult-to-treat atrial fibrillation in a patient on haemodialysis].
González Oliva
J C
JC
Saurina i Solé
A
A
Pou Potau
M
M
Salas Gama
K R
KR
Ramírez de Arellano Serna
M
M
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000638:Amiodarone / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D017298:Bisoprolol / Q000627:therapeutic use; D001919:Bradycardia / Q000209:etiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004077:Digoxin / Q000009:adverse effects / Q000627:therapeutic use; D004110:Diltiazem / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D009203:Myocardial Infarction / Q000150:complications; D010138:Pacemaker, Artificial; D006435:Renal Dialysis
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D004077:Digoxin; D004110:Diltiazem; D000638:Amiodarone; D017298:Bisoprolol